MARKETVUE® REPORT: Arrhythmogenic Cardiomyopathy Gene Therapy Research Gains MomentumAmanda Theocles2023-11-09T17:37:19+00:00November 9th, 2023|Read More
MARKETVUE® REPORT: Gene therapies for treatment of Glycogen Storage Disease Type 1a offer hope for overburdened patientsAmanda Theocles2023-09-28T15:14:46+00:00September 28th, 2023|Read More
Graves’ Disease patients face limited treatment options that do not irreversibly destroy the thyroid (MARKETVUE® REPORT)Amanda Theocles2023-09-12T13:59:07+00:00September 12th, 2023|Read More
Ophthalmologists estimate 10% of Geographic Atrophy patients are now treated with Syfovre since its February 2023 approval (MARKETVUE® REPORT)Amanda Theocles2023-09-12T13:53:49+00:00September 12th, 2023|Read More
MARKETVUE® REPORT: Arrhythmogenic Cardiomyopathy Gene Therapy Research Gains MomentumAmanda Theocles2023-11-09T17:37:19+00:00November 9th, 2023|Read More
MARKETVUE® REPORT: Gene therapies for treatment of Glycogen Storage Disease Type 1a offer hope for overburdened patientsAmanda Theocles2023-09-28T15:14:46+00:00September 28th, 2023|Read More
Graves’ Disease patients face limited treatment options that do not irreversibly destroy the thyroid (MARKETVUE® REPORT)Amanda Theocles2023-09-12T13:59:07+00:00September 12th, 2023|Read More
Ophthalmologists estimate 10% of Geographic Atrophy patients are now treated with Syfovre since its February 2023 approval (MARKETVUE® REPORT)Amanda Theocles2023-09-12T13:53:49+00:00September 12th, 2023|Read More
